ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundClinical tuberculosis (TB) research has been hampered by a lack of reliable predictors of Mycobacterium tuberculosis infection progression and active TB treatment's cure, relapse, and failure. Given host and bacterial variability, large sample sizes from harmonized datasets are needed to study infrequent endpoints. Therefore, global observational research consortia, such as Regional Prospective Observational Research in Tuberculosis (RePORT) International (RI), can help make meaningful inroads into successful TB prevention, diagnosis, and treatment.
methodsRePORT International was created in 2012 by the US National Institute of Allergy and Infectious Diseases (NIAID) with bilateral country funding. The Consortium's country networks (Brazil, India, Indonesia, Korea, Philippines, South Africa, and Uganda) use a common protocol to recruit for 2 participant cohorts (active TB and close contacts). A coordinating center, led by a multinational executive committee, provides early-stage investigator research and mentorship opportunities, guidance on quality-assured data and specimen collection, and scientific direction while allowing networks to pursue geographically relevant research and implementation.
resultsConsortium biorepositories house 632 000+ specimens with associated epidemiological data from ∼11 900 participants. There have been 67 country- and consortium-wide projects via multiple funding sources, resulting in about 200 publications covering epidemiology, drug resistance, biomarkers, comorbidities, transcriptomics, diagnostics, and immunology. Capacity building is conducted through research fellowships and collaborations with other consortia including with a public resource database and data/specimen dashboard.
conclusionsPublic health research has had funding limitations on ideal patient enrollment and follow-up, as well as the maintenance of research infrastructure and personnel. However, RI is well prepared to meet these challenges while supporting better point-of-care diagnostics, screening for asymptomatic TB, post-TB care, and successful treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.